Clover Biopharma returns to profit in H1 FY26 at RMB 954.98 million

PUBT · 3d ago
Clover Biopharma returns to profit in H1 FY26 at RMB 954.98 million
  • Clover Biopharmaceuticals swung to an IFRS profit of RMB 954.98 million, reflecting a one-off GAVI settlement gain.
  • Revenue fell 94.5% to RMB 179,000 due to the termination of AdimFlu-S (QIS) commercial activities in mainland China.
  • Other income and gains surged to RMB 1.11 billion, driven by RMB 1.09 billion gain on the GAVI settlement.
  • R&D expenses rose to RMB 104.84 million as the group continued investing in respiratory vaccine candidates.
  • Enrollment completed in an Australia Phase II study for SCB-1022 and SCB-1033; initial results expected in Q3 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clover Biopharmaceuticals Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260826-12299346), on August 25, 2026, and is solely responsible for the information contained therein.